

**Cardiology and Angiology: An International Journal**  
1(1): 23-33, 2013, Article no.CA.2013.003

SCIENCEDOMAIN *international*  
[www.sciencedomain.org](http://www.sciencedomain.org)



---

## Age Related Hemodynamic Blood Pressure Changes for Cardiovascular Disease and Stroke: A Mini-review

Steven G. Chrysant<sup>1\*</sup> and George S. Chrysant<sup>2</sup>

<sup>1</sup>Department of Cardiology, University of Oklahoma College of Medicine, Oklahoma City, OK, USA.

<sup>2</sup>Department of Cardiology, INTEGRIS Baptist Medical Center, Oklahoma City, OK, USA.

### **Authors' contributions**

*Both authors contributed equally in the preparation of the manuscript.*

**Mini-review**

**Received 3<sup>rd</sup> May 2013**  
**Accepted 22<sup>nd</sup> June 2013**  
**Published 12<sup>th</sup> July 2013**

---

### **ABSTRACT**

The blood pressure (BP) changes with the advancement of age from the predominant diastolic BP (DBP) in the young to the predominant systolic BP (SBP) in the older person. This shift is due to the stiffening of the large arteries as a result of the ageing process and the replacement of the elastic fibers with collagen fibers resulting in the loss of compliance and the elastic recoil of these vessels. The end result is augmentation in pulse wave velocity (PWV) and widening of pulse pressure (PP). The SBP rises linearly with the advancement of age whereas, the DBP rises up to the age 50 years and begins to decline after the age of 60 years leading to a progressive increase in PP. These hemodynamic changes of BP are frequently associated with an increased incidence in cardiovascular disease (CVD) and strokes. Several studies have shown an inverse relationship between DBP and CVD, whereas no such a relationship has been demonstrated for stroke. However, recently, an inverse relationship has been reported between DBP and stroke for subjects 50 years of age or older. The implications of BP changes with age as they are related to CVD and strokes will be discussed in this mini review. It appears from these recent findings that in treating the hypertension in the elderly to reduce CVD and stroke, care should be taken not to allow the DBP to drop below 55-80 mmHg, since below this DBP level the incidence of CVD and strokes increase.

---

\*Corresponding author: E-mail: [schrysant@yahoo.com](mailto:schrysant@yahoo.com);

*Keywords: Age; arteriosclerosis; systolic blood pressure; cardiovascular disease; stroke.*


## **1. INTRODUCTION**

Several epidemiologic studies have shown that the blood pressure (BP) changes with the advancement of age from the predominance of diastolic BP (DBP) in the young person to the predominance of systolic BP (SBP) in the older person. In addition our perception in treating the hypertension has shifted lately from focusing on treating the DBP, in treating the SBP. Also, the significance of office BP has been challenged recently as not being representative of a person's actual BP due to the introduction of new entities like white coat hypertension (WCH) and masked hypertension (MH), discovered with the use of ambulatory BP measurement (ABPM). These two BP entities have opposite meanings, where WCH is the condition with elevated BP in the doctor's office or clinic and normal BP outside the doctor's office measured either by ABPM or with a home BP monitor [1]. In contrast, MH is the condition with normal BP at the doctor's office and elevated BP outside the doctor's office measured by the same means [2]. The shift of focus from the treatment of DBP to the treatment of the SBP is due to the ageing of the population and the fact that the SBP is the predominant BP in this population [3]. Some authors have even gone to the extreme stating that "SBP is all that matters" [4]. This is a significant departure from the early years when the focus was on the treatment of DBP, since the SBP was considered a normal consequence of the ageing process. Even the reports of the National Committees on the Detection, Evaluation, and Treatment of High BP (JNCs) did not emphasize the treatment of SBP until their 5<sup>th</sup> report in 1993 [5]. Recently, it has been suggested that treating the hypertension, the age of the subject should be considered since the DBP is the predominant BP in the young and the SBP is the predominant BP in the older person. The DBP rises from childhood till the age of 50 years and then begins to decline after the age of 60 years, whereas the SBP rises linearly from adulthood to the old age. The significance of BP change with age was first pointed out by the Framingham study investigators [6]. Previous studies used the changes in BP in correlation with various age subgroups to determine its association with the risk of CVD and stroke [7-9]. It has been speculated that if age was used as a continuous variable, this could have given a clearer picture at which age the SBP begins to exceed the DBP with respect to stroke incidence. This concept was tested in two recent studies [10,11]. The significance of the findings from these studies regarding the relationship of BP changes with age regarding the incidence of CVD and stroke together with collateral literature will be discussed in this concise review.

### **1.1 Pathophysiology of Arteriosclerosis and Systolic Hypertension**


The large arteries in young persons possess two functions, a) to act as conduits transferring blood to vital organs and tissues, and b) to act as cushions to smooth out the pulsatile blood flow produced by the intermittent contractions of the heart into a continuous and steady blood flow [12]. However, as the person ages these functions of the large arteries are modified by the onset of arteriosclerosis, which is a consequence of the ageing of blood vessels. The primary cause of arteriosclerosis is the fragmentation of the elastic lamellae which become thinned, frayed, and are replaced with collagen tissue. This fragmentation of the elastic fibers is the result of the fatiguing effect produced over the years by the cycling stress of the pulsatile blood flow. In a young person [13], the elastic aorta expands during systole and absorbs part of the stroke volume (SV). During diastole the aorta recoils back and sends the retained SV distally, thus converting the intermittent blood flow into a continuous and steady blood flow (Fig. 1A). In an elderly person, the elasticity and

compliance of the aorta is lost [13] and most of the SV is transmitted distally during systole with practically no blood flow during diastole (Fig. 1B). The direct result of this function is an increase in SBP, a decrease in DBP and a widening of pulse pressure (PP). These latter changes lead to acceleration of pulse wave velocity (PWV), which is a diagnostic characteristic of arteriosclerosis. In addition, the morphology of the pressure wave also changes (Fig. 2).



**Fig. 1. A. The function of the central aorta in a younger person is depicted. During systole, the elastic aorta is dilated with each cardiac SV and functions as a reservoir (top filled arrow). As a result, not all SV is transmitted distally. During diastole, the elastic recoil of the aorta expels the remnant original SV to distal arteries and arterioles. This function results in a smooth contour of the arterial pulse wave (PW) and a narrow PP (bottom). B. In an older person, the aorta has lost most of its elasticity with a reduction of its reservoir capacity, which results in the expulsion of almost the entire SV to the distal arteries with practically no diastolic blood flow (top filled arrow). The result is a distortion of the arterial PW (bottom), an increase in SBP, a decrease in DBP, and a widening of PP**

*Adapted with permission from Franklin [13]*



**Fig. 2.** This figure depicts the configuration of the arterial waveforms in the younger (left) and older person (right). The arterial waveforms are composite waves (top heavy line), and are composed of a forward wave (dashed line) and a backward reflective wave (dotted line). The vertical line represents the closure of the aortic valve. The top solid line indicates the peak SBP in the younger (left) and the older person (right) together with the augmentation pressure. The reflected wave in the younger person (left) returns to the aortic root early in diastole augmenting the DBP, which helps the perfusion of the coronary arteries, whereas in the older person (right) it returns to the aortic root late in systole augmenting the SBP, which increases the left ventricular outflow pressure. Due to the arterial stiffness, the PWV is increased in the older person (12 m/sec) compared with the younger person (8 m/sec)

*Adapted with permission from Franklin [13]*

The pressure wave is a composite of the incident (forward) wave generated by the contraction of the heart and the reflected (backward) wave generated by the resistance of small vessels. In young persons, the reflected wave travels slower and reaches the central aorta in early diastole leading to augmentation of the DBP, which is useful for the perfusion of coronary arteries. In older persons, the reflected wave travels a lot faster and reaches the central aorta in late systole leading to augmentation of the central SBP causing an increase in the pressure load of the left ventricle and the development of left ventricular hypertrophy (LVH). The increased central aortic SBP is also associated with a higher incidence of CVD and strokes [14]. Also, the pulsatile stress produced by the intermittent action of the heart has been shown recently to increase the media layer of the small muscular arteries thus, decreasing their lumen and leading to further acceleration of PWV in older persons [15]. Pathophysiologically, the pressures in the large arteries (aorta, carotids) are more relevant than the peripheral (brachial) pressures for the pathogenesis of CVD and strokes. It is the central aortic SBP that the left ventricle encounters during systole (afterload) and not the DBP, which is mostly responsible for the perfusion of coronary arteries [16].


## 1.2 Pulse Pressure Amplification and Cardiovascular Disease Risk

The shape of pressure wave changes as it travels down the aorta resulting in augmentation of the peripheral SBP and PP as the distance from the heart increases, in contrast to DBP and mean arterial pressure (MAP), which change very little for the same distance from the heart. The merging of the forward and reflected pressure waves result in augmentation in SBP and PP but not a change in the DBP thus, leading to the widening of PP [17]. The degree of augmentation of SBP is higher in older persons than the younger persons and can be calculated from the difference between the first and second systolic peaks of the central aortic SBP (Fig. 2). From the augmentation of pressure (AP) and PP, the augmentation index (Alx) can be calculated as  $Alx = AP/PP$ . Clinical evidence from the Strong Heart Study has indicated that the peripheral PP is associated with a higher incidence of cardiovascular mortality, which was independent of LVH and the systolic dysfunction of the heart in the absence of overt coronary artery disease [18]. In addition, the 5 year follow-up of these patients showed that the non-invasively measured central PP was a better predictor of incident CVD than the brachial PP, since the former is a better representative of left ventricular pressure load. Also, a meta-analysis of studies in older persons showed that the PP was more strongly related to increased cardiovascular complications than MAP [19]. Moreover, an increased Alx has been shown to be, independently, associated with a higher risk of short-and-long-term cardiovascular events in patients undergoing percutaneous coronary interventions [20].

## 1.3 Changes of Blood Pressure with Age and Their Relationship to Stroke and CVD

The brain and the heart are protected against stroke and myocardial infarction through wide fluctuations of BP due to the autoregulation of cerebral and coronary artery circulation. Cerebral autoregulation (CA) is the intrinsic capacity of the cerebral vessels to maintain a constant cerebral blood flow (CBF) for the metabolic needs of the brain [21]. The CBF is also regulated, besides BP, by the arterial CO<sub>2</sub> level of the brain as well. The CBF consists of two components, the static and the dynamic component. The static CA regulates the CBF during gradual and progressive increases in BP [22], whereas the dynamic CA regulates the CBF during rapid changes in BP [22]. It has been demonstrated that the CBF remains constant through wide changes in MAP ranging from 60 to 150 mmHg (Fig. 3) or from 40 to 125 mmHg by transcranial Doppler [23]. From these studies it appears that the CBF is not seriously affected even with very low DBP, and this could explain the lack of a J curve effect for stroke incidence with low DBP in contrast to the heart which is susceptible to J curve effect with low DBP, since DBP is responsible for coronary artery perfusion [24]. However, a recent study has shown that there might be a J curve effect for stroke risk with a DBP < 71 mmHg in older persons [10]. In this study, 68,551 subjects 19 to 78 years old from several European countries free of CVD and not taking antihypertensive drugs at study entry, were followed for 13.2 years. The subjects were divided into 4 age groups, 19-39, 40-49, 50-59, and 60-78. The data showed that when the SBP and DBP were analyzed separately, both pressures were associated with a high stroke risk if they were  $\geq 71$  mmHg across all age groups ( $P < 0.001$ ). In contrast, when the SBP and DBP were considered together, the SBP became not significant in the 19-39 year olds, whereas the DBP became significant for stroke risk in the 60-78 year olds if dropped < 71 mmHg. Regarding the association of MAP with stroke risk, this was stronger in the younger age groups and declined progressively with advancing age becoming not significant after the age of 69 years for men and the age of 73 years in women. In addition, there was a significant association between PP and stroke risk,

which was independent of age and remained significant after multivariate adjustments. Similarly, in the study by Safar et al [11], in 4,293 hypertensive patients with or without the metabolic syndrome followed for 9 years (DESIR Study), the DBP was the strongest predictor for CVD in subjects < 50 years old, whereas the SBP was the strongest predictor for CVD in subject's  $\geq 60$  years old. After adjustments, there were no major differences in the findings in patients with or without the metabolic syndrome regarding the effects of age on BP changes. Besides the BP, the increased PP has also been demonstrated to be an important factor for CVD by these and other studies [17-20].



**Fig. 3. This figure depicts the CBF autoregulation and the range of perfusion pressures. An autoregulatory plateau is seen between 60 to 150 mmHg of MAP. This autoregulatory plateau is maintained through changes in cerebral vascular resistance (CVR). Once the limits of autoregulation are reached, CVR cannot correct for further changes in pressure as demonstrated by the MAP limits of < 60 (lower limit) and > 150 mmHg (upper limit)**

*Adapted with permission from Lucas et al. [21]*

## 2. DISCUSSION

New evidence now suggests that there is an association between age and BP regarding cardiovascular and stroke risk. In subjects  $\leq 50$  years old, the DBP remains a dominant factor for CVD and stroke risk, whereas in subjects  $\geq 60$  years of age, the SBP is the dominant risk factor [10,11]. In addition to BP there is also a sex effect with the MAP becoming not significant for stroke risk in men after the age of 69 and in women after the age of 73 years, since the MAP represents the DBP. Similar findings have also been reported by other investigators [11,25]. An important new finding is the inverse relationship between DBP and stroke risk in older persons. In subjects  $\geq 60$  years, there was an increased risk for stroke when the DBP dropped below 71 mmHg. Such an association is not commonly seen with strokes in contrast to CVD which depends on the DBP for coronary artery perfusion, and where the J curve effect has been demonstrated by several studies [24,26-30]. This finding has important clinical significance when treating elevated SBP in the elderly. Kannel et al [32] have shown that the incidence of CVD risk increased with a

decrease in DBP < 80 mmHg, when the SBP remained > 140 mmHg. Similarly, Fagard et al [31] recommend that in treating the systolic hypertension of older individuals, the treatment should be stopped if the DBP drops < 55 mmHg to prevent further widening of PP. In the study by Kannel et al. [32], the 10 year risk ratio (RR) for cardiovascular events for men and women was 1.22 (95% CI 0.97-1.50) when the PP was 46-55 mmHg, and the RR increased to 1.66 (95% CI 1.32-2.07) when the PP was 56-136 mmHg. The significance of PP as a cardiovascular [13, 17-20] and stroke risk [7,25,33,34] has also been demonstrated. This higher cardiovascular risk has been attributed to the increased pulsatile burden on the heart and blood vessels produced by the wide PP [34]. In this regard, the Framingham study tracked the age and sex of 4,993 participants for 28 years and demonstrated that the SBP and PP increased with age and were higher in older women compared to older men and were associated with a higher cardiovascular risk [34]. Given that both PP and chronological age are positively associated with a high cardiovascular and stroke risk, PP may be regarded as an index of arterial ageing. This could suggest that the biology of the ageing process differs between men and women. It has also, been suggested that the chronological age as determined by calendar time, is distinct from the biologic age, which is a progressive and irreversible process of deterioration of vital organ systems [33]. In addition, an inverse association has been found between PP and telomere length suggesting that the biologic age of persons with wide PP is more advanced than their chronological age would indicate [33]. With respect to the new findings regarding the interrelationships of BP with age regarding treatment of hypertension, both SBP and DBP are important up to the age of 50 years, after which the SBP becomes the dominant factor for cardiovascular and stroke complications. However, when treating the hypertension of older persons, attention should be paid that the level of DBP not be < 71 mmHg [10], or 80-55 mmHg, especially if the SBP remains  $\geq$  140 mmHg to avoid further widening of PP [11,29,31-34]. Although the risk for CVD and stroke appears to increase with a DBP below these levels, the National and International guidelines regarding treatment of hypertension, still recommend the BP to be < 130/80 mmHg for persons in high cardiovascular risk [35,36]. In contrast to these guidelines, some investigators recommend the SBP and DBP not to be lower than 130-139 and 80-90 mmHg, respectively [11,37]. Additionally, other investigators even propose to test the safety of SBP in the range of 130-150 mmHg [28]. These controversies require clarification from future studies. For the time being, the recommendations of National guidelines for the treatment of hypertension should remain in effect till new evidence becomes available. Regarding drug selection for the treatment of hypertension in older subjects, drugs that block the renin-angiotensin-aldosterone system (RAAS) alone or in combination with calcium channel blockers (CCB) are preferable as first line treatment in these individuals, since these drugs have been effective in lowering the central SBP and PP compared to beta blockers (atenolol) and thiazide diuretics as was demonstrated by the Conduit Artery Function Evaluation (CAFÉ) study [38]. In addition, the older beta blockers like atenolol have been shown to be less effective against stroke prevention [39]. Supporting the superior role of combination of RAAS blockers and CCBs, are the results of a recent Japanese study, which showed that the combination of RAAS blockers with CCBs was more effective in reducing the BP and cardiovascular complications than high dose RAAS blockers in high risk elderly hypertensive patients with or without renal failure [40]. With respect to the current practice of treating hypertension based on office measurements of BP, it would be prudent to, also measure the BP by ABPM before initiating treatment to diagnose the presence of WCH or MH. This is very important because treatment of WCH is, usually, not necessary [1], in contrast to MH where treatment is absolutely necessary, since MH is associated with a high incidence of cardiovascular complications and death [2]. Finally, it should be emphasized that despite of some differences in the action of the various antihypertensive drugs, the

focus should always be on good BP control and to this end, all classes of antihypertensive drugs should be used either alone or in combination.

### **3. CONCLUSION**

This concise review has presented evidence that the SBP increases linearly with the advancement of age and becomes the dominant factor for stroke risk after the age of 60 years. The BP change is due to arteriosclerosis and the stiffening of the large arteries as a consequence of the ageing process and results in the loss of their compliance and elastic recoil. These changes lead to increase in SBP, PP, and PWV, which, in turn increase the risk for CVD and strokes. New evidence suggests that there is a J-curve effect for stroke risk if the DBP < 71 mmHg in older persons. Therefore, care should be taken when treating resistant systolic hypertension in the elderly not to allow the DBP to drop below this level in order to prevent the widening of PP and its adverse effects on CVD and strokes. Regarding the treatment of SBP in the elderly, drugs that block the RAAS either alone or in combination with CCBs should be the first line of treatment, since these drugs are more effective in lowering the central SBP than other drugs. However, the focus should be on good BP control, and in this regard all drug classes should be utilized.

### **CONSENT**

Patient consent was not applicable for this study.

### **ETHICAL APPROVAL**

Ethical approval was not applicable for this study.

### **COMPETING INTERESTS**

The authors have nothing to declare and have no conflicts of interest.

### **REFERENCES**

1. Chrysant SG. White coat hypertension and white coat worst hypertension. In Mohler ER, Townsend RR, eds *Advanced Therapy in Hypertension and Vascular Disease*. Hamilton, CA, BC Dekker. 2006;537-543.
2. Pickering TG, Eguchi K, Kario K. Masked hypertension: a review. *Hypertens Res*. 2007;30:479-488.
3. Black HR. The paradigm has shifted to systolic blood pressure. *J Hum Hypertens*. 2004;18:S3-S7.
4. Williams B, Lindholm LH, Sever P. Systolic pressure is all that matters. *Lancet*. 2008;371:2219-2221.
5. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). *Arch Intern Med*. 1993;153:154-183.
6. Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease: the Framingham Study. *Am J Cardiol*. 1971;27:335-346.



7. Sesso HD, Stampfer MJ, Rosner B, Hennekens CH, Gaziano JM, Manson JE, et al. Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in men. *Hypertension*. 2000;36:801-807.
8. Miura K, Dyer AR, Greenland P, Daviglius ML, Liu K, Garside DB, et al. Pulse pressure compared with other blood pressure indexes in the prediction of 25-year cardiovascular and all-cause mortality rates: the Chicago Heart Association Detection Project in Industry Study. *Hypertension*. 2001;38:232-237.
9. Miura K, Soyama Y, Morikawa Y, Nishijo M, Nakanishi Y, Naruse Y, et al. Comparison of four blood pressure indexes for the prediction of 10-year stroke risk in middle-aged and older Asians. *Hypertension*. 2004;44:715-720.
10. Vishram JK, Borglykke A, Andreassen AH, Jeppersen J, Ibsen H, Jorgensen T, et al. on behalf of the MORGAM Project. Impact of age on the importance of systolic and diastolic blood pressure for stroke risk. The Monica, Risk, Genetics, Archiving, and Monograph (MORGAM) Project. *Hypertension*. 2012;60:1117-1123.
11. Safar ME, Balkau B, Lange C, Protogerou AD, Czernichow S, Blacher J, et al. Hypertension and vascular dynamics in men and women with the metabolic syndrome. *J Am Coll Cardiol*. 2013;61:12-19.
12. O'Rourke M. Mechanical principles of arterial disease. *Hypertension* 1995;26:2-9
13. Franklin SS, Izzo JL. Ageing, hypertension, and arterial stiffness. *Hypertension Primer 3<sup>rd</sup> edition*. Izzo JL, Black HR, editors, Lippinkott, Williams & Wilkins, Philadelphia, PA. 2003;170-174.
14. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure. The Strong Heart Study. *Hypertension*. 2007;50:197-203.
15. Muiesan ML, Salvetti M, Rizzoni D, Painsi A, Agapiti-Rosei E, Aggiusti C, et al. Pulsatile hemodynamics and microcirculation: Evidence for a close relationship in hypertensive patients. *Hypertension*. 2013;61:130-136.
16. Agapiti-Rosei E, Mancia G, O'Rourke MF, Roman MJ, Safar ME, Smulyan H, et al. Central blood pressure measurements and antihypertensive therapy. A consensus document. *Hypertension*. 2007;50:154-160.
17. Protogerou AD, Blacher J, Mavrikakis M, Lekakis J, Safar ME. Increased pulse pressure application in treated hypertensive subjects with metabolic syndrome. *Am J Hypertens*. 2007;20:127-133.
18. Palmieri V, Devereux RB, Hollywood J, Bella JN, Liu JE, Lee ET, et al. Association of pulse pressure with cardiovascular outcome is independent of left ventricular hypertrophy and systolic dysfunction: The Strong Heart Study. *Am J Hypertens*. 2006;19:602-607.
19. Blacher J, Staessen JA, Girerd X, Gasowski J, Thijs L, Liu I, et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. *Arch Intern Med*. 2000;160:1085-1089.
20. Weber T, Auer J, O'Rourke MF, Kvas E, Lassnig E, Lamm G, et al. Increased arterial wave reflections predict severe cardiovascular events in patients undergoing percutaneous coronary interventions. *Eur Heart J*. 2005;26:2657-2663.
21. Lucas SJ, Tseng YC, Galvin SD, Thomas KN, Ogoth S, Ainsley PN. Influence of changes in blood pressure on cerebral perfusion and oxygenation. *Hypertension*. 2010;55:698-705.
22. Paulson OB, Strangaard S, Edvisson L. Cerebral autoregulation. *Cerebrovasc Brain Metab Rev*. 1990;2:161-192.

23. Zhang R, Zuckerman JH, Iwasaki K, Wilson TE, Crandall CG, Levine BD. Autonomic neural control of dynamic cerebral autoregulation in humans. *Clin Med.* 2002;106:1814-1820.
24. Chrysant SG, Chrysant GS. Effectiveness of lowering blood pressure to prevent stroke versus to prevent coronary events. *Am J Cardiol.* 2010;106:825-829.
25. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WC, et al. Does the relation of blood pressure to coronary heart disease risk change with age?. The Framingham Heart Study. *Circulation.* 2001;103:1245-1249.
26. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH, Cutler JA, et al. The ACCORD Study Group. Effects of intensive blood pressure control in type 2 diabetes mellitus. *N Engl J Med.* 2010;362:1575-1585.
27. Messerli FH, Mancia G, Conti CR, Hawkin AC, Kupfer S, Champion A, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous ?, *Ann Intern Med.* 2006;144:884-893.
28. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, et al, on behalf of the ONTARGET Investigators. Prognostic value of blood pressure in patients with vascular risk in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial study. *J Hypertens.* 2009;27:1360-1369.
29. Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP for the PROVE IT-TIMI 22 Trial Investigators. What is the optimal blood pressure in patients after acute coronary syndrome ?. Relationship of blood pressure and cardiovascular events in the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in myocardial Infarction (PROVE IT-TIMI 22) trial. *Circulation.* 2010;122:2142-2151.
30. Psaty BM, Furberg CD, Kuller LH, Cushman H, Savage PI, Levine D, et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the Cardiovascular Heart Study. *Arch Intern Med.* 2002;161:1183-1192.
31. Fagard RH, Staessen JA, Thijs L, Celis H, Bulpitt CJ, de Leeuw PW, et al. On-treatment diastolic blood pressure and prognosis in systolic hypertension. *Arch Intern Med.* 2007;167:1884-1891.
32. Kannel WB, Wilson PW, Nam BH, D'Agustino RB, Li J. A likely explanation for the J-curve of blood pressure cardiovascular risk. *Am J Cardiol.* 2004;94:380-384.
33. Aviv A. Hypothesis: Pulse pressure and human longevity. *Hypertension.* 2001;37:1060-1066.
34. Cheng S, Xanthakis V, Sullivan LM, Vasan RS. Blood pressure tracking over the adult life course. Patterns and Correlates in the Framingham Heart Study. *Hypertension* 2012;60:1393-1399.
35. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension.* 2003;42:1206-1252.
36. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). *J Hypertens.* 2007;25:1105-1187.
37. Mancia G, Laurent S, Agapiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. *J Hypertens.* 2009;27:2121-2158.

38. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFÉ) study. *Circulation*. 2006;113:1213-1225.
39. Chrysant SG, Chrysant GS. Current status of b-blockers for the treatment of hypertension; an update. *Drugs of Today*. 2012;48:353-366.
40. Kim-Mitsuyama S, Ogawa H, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K, et al. An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease is better than high-dose angiotensin II receptor blocker alone. *Kidney Int*. 2012;83:167-176.

---

© 2013 *Chrysant and Chrysant*; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Peer-review history:*

*The peer review history for this paper can be accessed here:*  
<http://www.sciencedomain.org/review-history.php?iid=221&id=26&aid=1647>